THE ROLE OF EDUCATION IN FOSTERING ENTREPRENEURSHIP AND INNOVATION: INSIGHTS FROM DR. BHAVNA AMBUDKAR
Background: Dr. Bhavna, an experienced leader in education and innovation, has held various leadership positions, including head of department, dean of alumni relations, and president of the institutions innovation council. She has been instrumental in initiating the alumni cell at her previous organization and establishing world-class state-of-the-art laboratories in collaboration with the automotive sector. Aims: Dr. Bhavna's efforts aim to create an ecosystem for innovation and entrepreneurship within the institute and beyond, encouraging learners to consider entrepreneurship as a career option and fostering innovation in the electronics manufacturing domain. Methods: Dr. Bhavna's approach involves raising awareness about innovation and entrepreneurship among learners, fostering collaborations between academia and industry, and establishing world-class state-of-the-art laboratories to bridge the gap between academia and industry. Results: Dr. Bhavna's efforts have resulted in a strong alumni network, with graduates across the globe contributing to various domains and positions. She has also established world-class laboratories in collaboration with the automotive sector, fostering innovation and startups in the electronics manufacturing domain. Discussions: The Ministry of Electronics and Information Technology plays a significant role in initiating innovations and startups in the electronics manufacturing domain. They have generated a separate vertical for startups, which poses challenges to innovators. If a solution is validated, the ministry handholds the innovators, incubates their ideas, funds them, and helps them reach the market at the national and international levels. Conclusions: Dr. Bhavna's vision and efforts toward fostering an ecosystem for innovation and entrepreneurship within the institute and beyond are commendable. Her experience and achievements in various leadership roles, including as the head of the department and president of the institutions innovation council, have added significant value to her professional and personal life.
Read ArticleCLINICAL AND LABORATORY TESTING OF A NEW MODIFICATION OF TWO-LAYER "SILEP" DENTURES USED IN PROSTHETIC DENTISTRY
Dentistry is a part of medicine, where various polymer materials were used for the first time. Many factors forced researchers to find more stable, versatile, and hygienic materials for the manufacture of dental products. It is important to note that the search for the ideal polymer dental material is still ongoing. This is because modern polymers, in some cases, do not meet the specified requirements for chemical, physical, strength, and elasticproperties. Based on the data on the method of creating and using silicone material for the base of the removable prosthesis "Gossil", an improved silicone material for two-layer dentures "Silep" was developed, as well as a special primer for better connection of the lining with the rigid acrylic base of the prosthesis. To evaluate the most suitable compound, materials were tested for several parameters, such as tensile strength, elongation, and shore hardness. In addition to selecting a suitable material for modification, the selection and testing of an adhesive that allows the chemical bonding of the acrylate surface to the siloxane surface were carried out.
Read ArticleTREATMENTS FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A COMPARISON BETWEEN TISAGENLECLEUCEL AND CLOFARABINE
Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous hematological malignancy predominantly affecting individuals under 20 years of age. Traditional chemotherapy, such as clofarabine, has shown efficacy; however, novel immunotherapeutic strategies like tisagenlecleucel (Kymriah®) have significantly altered the treatment paradigm. Aim: This study aimed to perform a comparative analysis of tisagenlecleucel, a CAR-T cell therapy, and clofarabine, a second-generation purine nucleoside analog, evaluating their mechanisms of action, therapeutic benefits, limitations, and clinical applicability across diverse patient populations. Methods: A systematic comparative evaluation was conducted, encompassing pharmacological characteristics, mechanisms of action, treatment protocols, efficacy, safety profiles, and clinical indications of both agents. The analysis considered pharmacokinetic and pharmacodynamic data and included patient demographic variables. Results: Tisagenlecleucel demonstrated high efficacy in refractory B-cell ALL, with durable responses and a blood half-life of 128 days, but with notable immune-related adverse effects such as cytokine release syndrome. Clofarabine, effective across a broader patient population, acts via multiple antitumor mechanisms but carries significant toxicity risks, including infection and sepsis. Discussion: The therapies present distinct clinical profiles: tisagenlecleucel offers targeted immunotherapy with high specificity but requires specialized infrastructure and management of immune toxicities. Clofarabine is more widely accessible and applicable, but is associated with conventional chemotherapy-related side effects. Treatment accessibility and cost differ markedly between the two. Conclusions: Therapy selection should be personalized based on patient-specific factors and institutional resources. Tisagenlecleucel is ideal for pediatric and young adult patients with relapsed/refractory B-cell ALL in CAR-T-capable centers, while clofarabine remains a viable option for broader ALL populations, particularly when genetic therapies are not feasible. Further research is needed to optimize therapeutic strategies and improve access to advanced treatments.
Read Article